Artemis Global Life Sciences Ltd((Merged)
Artemis Global Life Sciences is engaged in Healthcare Services.
- Market Cap ₹ 327 Cr.
- Current Price ₹ 49.4
- High / Low ₹ /
- Stock P/E 15.6
- Book Value ₹ 44.3
- Dividend Yield 0.00 %
- ROCE 13.6 %
- ROE 7.65 %
- Face Value ₹ 2.00
Pros
- Stock is trading at 1.12 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 9.65% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | TTM | |
|---|---|---|---|---|
| 463 | 503 | 547 | 556 | |
| 411 | 443 | 481 | 489 | |
| Operating Profit | 52 | 60 | 66 | 67 |
| OPM % | 11% | 12% | 12% | 12% |
| 5 | 3 | 2 | 3 | |
| Interest | 9 | 9 | 11 | 12 |
| Depreciation | 15 | 19 | 20 | 21 |
| Profit before tax | 33 | 35 | 37 | 37 |
| Tax % | 17% | 25% | 45% | |
| 27 | 26 | 20 | 21 | |
| EPS in Rs | 4.10 | 3.97 | 3.10 | 3.18 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 10% |
| Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|
| Equity Capital | 13 | 13 | 13 |
| Reserves | 234 | 260 | 280 |
| 94 | 91 | 76 | |
| 129 | 133 | 185 | |
| Total Liabilities | 469 | 497 | 554 |
| 326 | 352 | 381 | |
| CWIP | 27 | 43 | 49 |
| Investments | 0 | 0 | 0 |
| 116 | 102 | 124 | |
| Total Assets | 469 | 497 | 554 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|
| 52 | 71 | 40 | |
| -70 | -67 | -50 | |
| 22 | -10 | 14 | |
| Net Cash Flow | 4 | -5 | 5 |
| Free Cash Flow | -19 | 10 | -17 |
| CFO/OP | 103% | 121% | 76% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|
| Debtor Days | 48 | 40 | 52 |
| Inventory Days | |||
| Days Payable | |||
| Cash Conversion Cycle | 48 | 40 | 52 |
| Working Capital Days | -24 | -26 | -36 |
| ROCE % | 13% | 14% |
Documents
Announcements
- Compliance Certificate Under Regulation 40(9) Of The SEBI (LODR) Regulations, 2015 ('Listing Regulations') 22 Oct 2019
- Shareholding for the Period Ended September 30, 2019 16 Oct 2019
-
Statement Of Investor Complaints For The Quarter Ended September 2019
15 Oct 2019 - No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Oct 2019 - Notice published in the Newspaper - Intimation about the Record Date of the Composite Scheme of Amalgamation between Artemis Global Life Sciences Limited ('Company'), Artemis …
- Fixation Of Record Date - Regulation 30 And 42 Of SEBI (LODR) Regulations, 2015 (Revised) 14 Oct 2019